Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Filgotinib in Active Psoriatic Arthritis with Inadequate Response or Intolerance to Biologic DMARDs
jRCT2080225106Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in psoriatic arthritis (PsA) (3 arms), sponsored by Gilead Sciences. Started Mar 2020; status: completed.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2080225106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225106.